Title : Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.

Pub. Date : 2015

PMID : 26200905






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens
2 We evaluated the significance of RRM1 and ERCC1 expression to predict tumor response to gemcitabine plus platinum chemotherapy (GP) and survival in advanced UC. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens
3 RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens